vs
Side-by-side financial comparison of Aspire Biopharma Holdings, Inc. (ASBP) and PALISADE BIO, INC. (PALI). Click either name above to swap in a different company.
Aspire Biopharma Holdings, Inc. is a clinical-stage biopharmaceutical firm focused on developing novel therapeutic candidates for unmet needs in oncology and rare diseases, with primary operations across North America and key Asia-Pacific markets.
Palisade Bio, Inc. is a clinical-stage biopharmaceutical firm developing novel therapies for gastrointestinal and associated inflammatory disorders. Its lead product candidates address unmet medical needs including post-surgical intestinal complications and chronic digestive conditions, operating primarily in the U.S. healthcare market.
ASBP vs PALI — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.9K | $0 |
| Net Profit | $-1.9M | — |
| Gross Margin | 45.5% | — |
| Operating Margin | -59015.8% | — |
| Net Margin | -95337.1% | — |
| Revenue YoY | — | — |
| Net Profit YoY | -755.6% | — |
| EPS (diluted) | $-0.04 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $0 | ||
| Q3 25 | $1.9K | $0 | ||
| Q2 25 | — | $0 | ||
| Q1 25 | — | $0 | ||
| Q4 24 | — | $0 | ||
| Q3 24 | — | $0 | ||
| Q2 24 | — | $0 | ||
| Q1 24 | — | $0 |
| Q4 25 | — | — | ||
| Q3 25 | $-1.9M | $-2.9M | ||
| Q2 25 | — | $-2.8M | ||
| Q1 25 | — | $-2.2M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-3.5M | ||
| Q2 24 | — | $-4.1M | ||
| Q1 24 | — | $-3.5M |
| Q4 25 | — | — | ||
| Q3 25 | 45.5% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | -59015.8% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | -95337.1% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | $-0.04 | $-0.38 | ||
| Q2 25 | — | $-0.58 | ||
| Q1 25 | — | $-0.47 | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-2.32 | ||
| Q2 24 | — | $-3.32 | ||
| Q1 24 | — | $-4.59 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $133.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-11.5M | $129.4M |
| Total Assets | $2.4M | $134.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $133.4M | ||
| Q3 25 | — | $5.2M | ||
| Q2 25 | — | $5.4M | ||
| Q1 25 | — | $7.2M | ||
| Q4 24 | — | $9.8M | ||
| Q3 24 | — | $8.0M | ||
| Q2 24 | — | $11.4M | ||
| Q1 24 | — | $11.3M |
| Q4 25 | — | $129.4M | ||
| Q3 25 | $-11.5M | $3.2M | ||
| Q2 25 | — | $2.6M | ||
| Q1 25 | — | $5.3M | ||
| Q4 24 | — | $7.5M | ||
| Q3 24 | — | $6.6M | ||
| Q2 24 | — | $9.9M | ||
| Q1 24 | — | $10.1M |
| Q4 25 | — | $134.3M | ||
| Q3 25 | $2.4M | $7.0M | ||
| Q2 25 | — | $6.7M | ||
| Q1 25 | — | $8.2M | ||
| Q4 24 | — | $10.9M | ||
| Q3 24 | — | $9.3M | ||
| Q2 24 | — | $12.9M | ||
| Q1 24 | — | $12.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.1M | $-10.8M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-10.8M | ||
| Q3 25 | $-1.1M | $-3.6M | ||
| Q2 25 | — | $-1.8M | ||
| Q1 25 | — | $-2.3M | ||
| Q4 24 | — | $-12.2M | ||
| Q3 24 | — | $-3.1M | ||
| Q2 24 | — | $-3.5M | ||
| Q1 24 | — | $-3.2M |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
